The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

June 6, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has approved a label update for the ixekizumab injection, which will include data on psoriasis involving the genital area. This label update is based on the results of a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriasis involving the genital area.1

You Might Also Like
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
  • Ixekizumab Clinical Trials Continue; FDA Updates Warning Label for Varenicline
  • Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
Explore This Issue
July 2018
Also By This Author
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss

During the study, plaque psoriasis patients (N=149) who were candidates for phototherapy or systemic therapy and failed to respond to at least one topical psoriasis treatment affecting the genital area, as well as those who were intolerant of at least one topical therapy affecting the genital area, were randomized to receive ixekizumab or placebo. These patients were required to have a minimum body surface area involvement of 1%, a static Physician Global Assessment (sPGA) and an sPGA genitalia score of at least 3.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 12, ixekizumab-treated patients had significant improvement in sPGA (genitalia score) compared with placebo-treated patients. Additionally, ixekizumab-treated patients had improvements in overall sPGA, genital itch (as measured by the Genital Psoriasis Symptoms Scalp Itch [GPSS] numeric rating scale) and patients’ perceived effects of psoriasis on frequency of sexual activity (measured by the Sexual Frequency Questionnaire item 2 score).

Results for ixekizumab and placebo, respectively, for sPGA genitalia of 0 (clear) or 1 (minimal) were 73% and 8%, 73% and 3% for the overall sPGA. The results for GPSS genital Itch (at least a four-point improvement) were 55% and 6%, respectively; and 78% and 21% for the SFQ score of “0” (never) or “1” (rarely), respectively.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ixekizumab is the first agent approved for treating moderate to severe plaque psoriasis to include labeling for psoriasis in the genital area. According to the drug’s manufacturer, up to 63% of psoriasis patients will be affected by genital-area psoriasis at some point in their lifetime.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Eli Lilly and Company. News release: Lilly’s Taltz (ixekizumab) receives the first U.S. FDA approval for label update to include data for psoriasis involving the genital area. 2018 May 22.

Filed Under: Conditions, Drug Updates Tagged With: FDA, genital psoriasis, ixekizumab, Psoriasis, U.S. Food and Drug Administration (FDA)Issue: July 2018

You Might Also Like:
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
  • Ixekizumab Clinical Trials Continue; FDA Updates Warning Label for Varenicline
  • Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
  • Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.